In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Coherus Oncology Inc (NASDAQ: CHRS) was $1.7 for the day, down -1.73% from the previous closing price of $1.73. In other words, the price has decreased by -$1.73 from its previous closing price. On the day, 0.77 million shares were traded. CHRS stock price reached its highest trading level at $1.78 during the session, while it also had its lowest trading level at $1.68.
Ratios:
Our analysis of CHRS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.43 and its Current Ratio is at 1.44. In the meantime, Its Debt-to-Equity ratio is 0.45 whereas as Long-Term Debt/Eq ratio is at 0.44.
On August 16, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $4 to $1.50.
On November 17, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $11.Robert W. Baird initiated its Outperform rating on November 17, 2023, with a $11 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 23 ’25 when Wahlstrom Mats sold 99,988 shares for $0.74 per share. The transaction valued at 73,881 led to the insider holds 0 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CHRS now has a Market Capitalization of 197586368 and an Enterprise Value of 978367. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.38 while its Price-to-Book (P/B) ratio in mrq is 1.65. Its current Enterprise Value per Revenue stands at 0.004 whereas that against EBITDA is -0.012.
Stock Price History:
The Beta on a monthly basis for CHRS is 0.97, which has changed by 1.3513141 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, CHRS has reached a high of $2.43, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is 12.69%, while the 200-Day Moving Average is calculated to be 55.20%.
Shares Statistics:
CHRS traded an average of 1.26M shares per day over the past three months and 891900 shares per day over the past ten days. A total of 116.22M shares are outstanding, with a floating share count of 105.68M. Insiders hold about 9.07% of the company’s shares, while institutions hold 46.58% stake in the company. Shares short for CHRS as of 1760486400 were 30165888 with a Short Ratio of 24.01, compared to 1757894400 on 31866663. Therefore, it implies a Short% of Shares Outstanding of 30165888 and a Short% of Float of 26.99.
Earnings Estimates
. The current rating of Coherus Oncology Inc (CHRS) reflects the combined expertise of 2.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.12 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$1.31 and -$1.31 for the fiscal current year, implying an average EPS of -$1.31. EPS for the following year is -$0.79, with 2.0 analysts recommending between -$0.44 and -$1.13.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 5 analysts. It ranges from a high estimate of $15M to a low estimate of $12M. As of. The current estimate, Coherus Oncology Inc’s year-ago sales were $70.77MFor the next quarter, 5 analysts are estimating revenue of $15.76M. There is a high estimate of $17.57M for the next quarter, whereas the lowest estimate is $12M.
A total of 4 analysts have provided revenue estimates for CHRS’s current fiscal year. The highest revenue estimate was $49.2M, while the lowest revenue estimate was $42.02M, resulting in an average revenue estimate of $46.27M. In the same quarter a year ago, actual revenue was $266.96MBased on 5 analysts’ estimates, the company’s revenue will be $96.91M in the next fiscal year. The high estimate is $161.64M and the low estimate is $61.94M.
